Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
KalVista Pharmaceuticals (KALV)
NASDAQ:KALV
RESEARCH TOOLSreports
Holding KALV?
Track your performance easily
KALV Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.97 - $16.88
Previous Close$8.36
Volume1.01M
Average Volume (3M)397.93K
Market Cap
$399.79M
Enterprise Value$270.23M
Total Cash (Recent Filing)$135.78M
Total Debt (Recent Filing)$6.21M
Price to Earnings (P/E)―
Beta1.34
Next Earnings
Mar 12, 2025EPS Estimate
-$0.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.64
Shares Outstanding49,417,986
10 Day Avg. Volume380,798
30 Day Avg. Volume397,927
Standard Deviation0.25
R-Squared0.03
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)3.08
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.69
Forecast
1Y Price Target
$24.20Price Target Upside189.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
KalVista Pharmaceuticals News
PremiumCompany Announcements
KalVista Pharmaceuticals Appoints New COO Amid Strategic Growth
PremiumCompany Announcements
KalVista Pharmaceuticals Reports Progress in HAE Treatment
PremiumPre-Earnings
Is KALV a Buy, Before Earnings?
PremiumCompany Announcements
KalVista Pharmaceuticals Appoints Laurence Reid to BoardBulls Say, Bears Say
Bulls Say
Competitive AdvantageSebetralstat will benefit from first to market advantage, if approved.
Drug ApprovalSebetralstat Ph3 data is highly supportive of an approval.
Market PotentialSebetralstat could fill this unmet need with a compelling efficacy and safety profile combined with the clear desire for convenient oral therapies.
Bears Say
CompetitionDeucrictibant is positioned as a potential competitor to sebetralstat.
Regulatory MilestonesStock remains flat despite significant achievements such as NDA filing.
Stock PerformanceStock has been flattish despite major milestones like phase III success.
---
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
KALV FAQ
What was KalVista Pharmaceuticals’s price range in the past 12 months?
KalVista Pharmaceuticals lowest stock price was $7.97 and its highest was $16.88 in the past 12 months.
What is KalVista Pharmaceuticals’s market cap?
Currently, no data Available
When is KalVista Pharmaceuticals’s upcoming earnings report date?
KalVista Pharmaceuticals’s upcoming earnings report date is Mar 12, 2025 which is in 80 days.
How were KalVista Pharmaceuticals’s earnings last quarter?
KalVista Pharmaceuticals released its earnings results on Dec 05, 2024. The company reported -$0.91 earnings per share for the quarter, missing the consensus estimate of -$0.908 by -$0.002.
Is KalVista Pharmaceuticals overvalued?
According to Wall Street analysts KalVista Pharmaceuticals’s price is currently Undervalued.
Does KalVista Pharmaceuticals pay dividends?
KalVista Pharmaceuticals does not currently pay dividends.
What is KalVista Pharmaceuticals’s EPS estimate?
KalVista Pharmaceuticals’s EPS estimate is -$0.88.
How many shares outstanding does KalVista Pharmaceuticals have?
KalVista Pharmaceuticals has 49,417,988 shares outstanding.
What happened to KalVista Pharmaceuticals’s price movement after its last earnings report?
KalVista Pharmaceuticals reported an EPS of -$0.91 in its last earnings report, missing expectations of -$0.908. Following the earnings report the stock price went down -4.228%.
Which hedge fund is a major shareholder of KalVista Pharmaceuticals?
Among the largest hedge funds holding KalVista Pharmaceuticals’s share is Woodline Partners LP. It holds KalVista Pharmaceuticals’s shares valued at 7M.
---
KalVista Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.20 (189.47% Upside)
$24.20 (189.47% Upside)
Blogger Sentiment
Bullish
KALV Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 554.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 6.5%
Last 30 Days ▼ 6.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.00%
12-Months-Change
Fundamentals
Return on Equity
-125.90%
Trailing 12-Months
Asset Growth
15.92%
Trailing 12-Months
Company Description
KalVista Pharmaceuticals
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: hereditary angioedema (HAE) and diabetic macular edema (DME). The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello and is headquartered in Cambridge, MA.
---
KALV Stock 12 Month Forecast
Average Price Target
$24.20
▲(189.47% Upside)
Technical Analysis
Best Analysts Covering KALV
1 Year
1 Year Success Rate
10/21 ratings generated profit
1 Year Average Return
+4.22%
reiterated a buy rating 16 days ago
Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 47.62% of your transactions generating a profit, with an average return of +4.22% per trade.
---